IL33 and neoplasm: Emerging studies in the past decade have found IL-33 and IL-25 to either promote or inhibit CRC under different settings (Figures 3 and 4), and is likely dependent on the CRC subtype, tumour immunogenicity and the different immune cell populations involved (Table 1).